Hybrid Nanogel Drug Delivery Systems: Transforming the Tumor Microenvironment Through Tumor Tissue Editing

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Jun 19

PMID 38891040

Authors

Theodora Katopodi

Savvas Petanidis

George Floros

Konstantinos Porpodis

Christoforos Kosmidis

Affiliations

Soon will be listed here.

Abstract

The future of drug delivery offers immense potential for the creation of nanoplatforms based on nanogels. Nanogels present a significant possibility for pharmaceutical advancements because of their excellent stability and effective drug-loading capability for both hydrophobic and hydrophilic agents. As multifunctional systems, composite nanogels demonstrate the capacity to carry genes, drugs, and diagnostic agents while offering a perfect platform for theranostic multimodal applications. Nanogels can achieve diverse responsiveness and enable the stimuli-responsive release of chemo-/immunotherapy drugs and thus reprogramming cells within the TME in order to inhibit tumor proliferation, progression, and metastasis. In order to achieve active targeting and boost drug accumulation at target sites, particular ligands can be added to nanogels to improve the therapeutic outcomes and enhance the precision of cancer therapy. Modern "immune-specific" nanogels also have extra sophisticated tumor tissue-editing properties. Consequently, the introduction of a multifunctional nanogel-based drug delivery system improves the targeted distribution of immunotherapy drugs and combinational therapeutic treatments, thereby increasing the effectiveness of tumor therapy.

Citing Articles

Hydrogels with Essential Oils: Recent Advances in Designs and Applications.

Chelu M Gels. 2024; 10(10).

PMID: 39451288 PMC: 11508064. DOI: 10.3390/gels10100636.

References

Liu M, Cao Z, Zhang R, Chen Y, Yang X . Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy. ACS Appl Mater Interfaces. 2021; 13(29):33874-33884. DOI: 10.1021/acsami.1c08285. View

Sau S, Alsaab H, Bhise K, Alzhrani R, Nabil G, Iyer A . Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. J Control Release. 2018; 274:24-34. PMC: 5847475. DOI: 10.1016/j.jconrel.2018.01.028. View

Xu J, Qiu W, Liang M, Ye M, Hu J, Ma X . Dual-stimulus phototherapeutic nanogel for triggering pyroptosis to promote cancer immunotherapy. J Control Release. 2023; 358:219-231. DOI: 10.1016/j.jconrel.2023.04.030. View

Hu H, Feng W, Qian X, Yu L, Chen Y, Li Y . Emerging Nanomedicine-Enabled/Enhanced Nanodynamic Therapies beyond Traditional Photodynamics. Adv Mater. 2021; 33(12):e2005062. DOI: 10.1002/adma.202005062. View

Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Diez-Pascual A . Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. J Control Release. 2022; 349:844-875. DOI: 10.1016/j.jconrel.2022.07.036. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Li W, Peng A, Wu H, Quan Y, Li Y, Lu L . Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy. Front Immunol. 2021; 11:601497. PMC: 7779686. DOI: 10.3389/fimmu.2020.601497. View

Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R . Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Lett. 2021; 21(5):2224-2231. DOI: 10.1021/acs.nanolett.0c05039. View

Shah S, Rangaraj N, Laxmikeshav K, Sampathi S . "Nanogels as drug carriers - Introduction, chemical aspects, release mechanisms and potential applications". Int J Pharm. 2020; 581:119268. DOI: 10.1016/j.ijpharm.2020.119268. View

10.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

11.

Tang L, Fu C, Liu H, Yin Y, Cao Y, Feng J . Chemoimmunotherapeutic Nanogel for Pre- and Postsurgical Treatment of Malignant Melanoma by Reprogramming Tumor-Associated Macrophages. Nano Lett. 2024; 24(5):1717-1728. DOI: 10.1021/acs.nanolett.3c04563. View

12.

Wu Y, Yao Y, Zhang J, Gui H, Liu J, Liu J . Tumor-Targeted Injectable Double-Network Hydrogel for Prevention of Breast Cancer Recurrence and Wound Infection via Synergistic Photothermal and Brachytherapy. Adv Sci (Weinh). 2022; 9(24):e2200681. PMC: 9403641. DOI: 10.1002/advs.202200681. View

13.

Liu K, Cui J, Zhan Y, Ouyang Q, Lu Q, Yang D . Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol Cancer. 2022; 21(1):98. PMC: 8996591. DOI: 10.1186/s12943-022-01561-5. View

14.

Zhang Y, Zou Z, Liu S, Miao S, Liu H . Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics. Front Bioeng Biotechnol. 2022; 10:954470. PMC: 9343834. DOI: 10.3389/fbioe.2022.954470. View

15.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

16.

Macchione M, Biglione C, Strumia M . Design, Synthesis and Architectures of Hybrid Nanomaterials for Therapy and Diagnosis Applications. Polymers (Basel). 2019; 10(5). PMC: 6415435. DOI: 10.3390/polym10050527. View

17.

Ramasamy T, Ruttala H, Munusamy S, Chakraborty N, Kim J . Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J Control Release. 2022; 352:861-878. DOI: 10.1016/j.jconrel.2022.10.050. View

18.

Wang H, Gao L, Fan T, Zhang C, Zhang B, Al-Hartomy O . Strategic Design of Intelligent-Responsive Nanogel Carriers for Cancer Therapy. ACS Appl Mater Interfaces. 2021; 13(46):54621-54647. DOI: 10.1021/acsami.1c13634. View

19.

Sun M, Shi W, Wu Y, He Z, Sun J, Cai S . Immunogenic Nanovesicle-Tandem-Augmented Chemoimmunotherapy via Efficient Cancer-Homing Delivery and Optimized Ordinal-Interval Regime. Adv Sci (Weinh). 2022; :e2205247. PMC: 9811449. DOI: 10.1002/advs.202205247. View

20.

Cheng F, Su T, Zhou S, Liu X, Yang S, Lin S . Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Sci Adv. 2023; 9(28):eade6257. PMC: 10348685. DOI: 10.1126/sciadv.ade6257. View